Educational reference only. Not medical advice. Nothing on this site is for sale.
Latest
CompoundingHHS lets 503A pharmacies compound six peptides under an interim enforcement discretion policyTrial resultRetatrutide beats Ozempic on blood sugar and weight in head-to-head TRANSCEND-T2D-2 trialFDA approvalFDA extends once-weekly insulin icodec (Awiqli) to children 10 and older with type 2 diabetesCompoundingCitizen petition asks FDA not to allow compounding of seven peptides reviewed by its advisory committeeTrial resultSurvodutide SYNCHRONIZE-2 phase 3 results in obesity with type 2 diabetes published in NEJMTrial resultEloraTZP (eloralintide plus tirzepatide) phase 2 results presented at EASD 2026Trial resultOrforglipron ACHIEVE-4 cardiovascular safety trial published in The LancetTrial resultFull TRIUMPH-2 retatrutide results published in The LancetFDA approvalFDA approves insulin efsitora alfa (Onswik), a once-weekly basal insulin for type 2 diabetesWADAWADA publishes 2027 Prohibited List, naming peptides as examples of non-approved substances
Sign in

Gastrointestinal

Teduglutide

Also called Gattex, Revestive, ALX-0600

Teduglutide is a longer-lasting version of GLP-2, a gut hormone that helps the intestine grow and absorb nutrients. It is used in people with short bowel syndrome who depend on IV nutrition, to help reduce how much IV support they need.

FDA-approvedApproved by the FDA for at least one use after large human trials.

All printable flashcards

Drawn from its published sequence: 33 residues, one bead each.

Overview

Teduglutide is a longer-lasting version of GLP-2, a gut hormone that helps the intestine grow and absorb nutrients. It is used in people with short bowel syndrome who depend on IV nutrition, to help reduce how much IV support they need.

How it works

Established: teduglutide binds GLP-2 receptors on intestinal cells and nerves, triggering local release of IGF-1, nitric oxide and keratinocyte growth factor. GLP-2 also increases blood flow to the gut and reduces stomach acid. The net effect is more absorptive intestinal surface.

What research shows

  • Adult placebo-controlled studies: abdominal pain 30% vs 22%, abdominal distension 20% vs 2%, fluid overload 12% vs 7% (FDA label).

Doses studied in people

Study or labelDose usedSource
FDA label, short bowel syndrome, adults and children 1+0.05 mg/kg subcutaneously once daily2
FDA label, moderate/severe renal impairment or end-stage renal disease (eGFR <60), adults and children 1+0.025 mg/kg once daily2

Label doses shown.

Read this first: these are the amounts given to participants in published studies or written on official prescribing labels, reported for reference. They are not recommendations. Trial doses were chosen for specific patients under medical supervision, and a dose that is safe in one person can be harmful in another.

Weekly protocol

How the schedule looks week by week. Each chart says where it comes from: a prescribing label, a clinical trial, or a protocol commonly reported online.

Gattex label dosing

Prescribing label

One week

D1D2D3D4D5D6D7

Once daily · Subcutaneous injection

Dose by week

0.05 mg/kgwk 1+
Course
Ongoing
Note
For adults and children 1 year and older with short bowel syndrome; use 0.025 mg/kg daily if eGFR is below 60 mL/min/1.73 m².
Source
GATTEX (teduglutide) prescribing information (FDA, revised 01/2021)

Reference only, not a recommendation. Label and trial schedules were set for specific patients under medical supervision. Use the calculator only to understand the arithmetic.

Safety

  • May speed growth of existing tumors, including colon polyps; colonoscopy before and during treatment (label).
  • Intestinal obstruction, gallbladder/bile duct and pancreatic disease (label).
  • Fluid overload including heart failure; can increase absorption of other oral drugs such as benzodiazepines (label).
  • Common: abdominal pain, nausea, upper respiratory infection, abdominal swelling, injection-site reactions, vomiting (label).

Report side effects of any drug or product to the FDA through MedWatch. For a possible poisoning in the US, call Poison Control at 1-800-222-1222.

Storage and stability

Vials refrigerated at 2–8°C before dispensing; do not freeze (label).

General lab handling, not instructions for personal use. See Storage and stability.

History

FDA-approved in 2012 for adults with short bowel syndrome, with a REMS safety program from December 2012. The label now covers patients 1 year and older. On August 26, 2026 the FDA removed the REMS, judging it no longer necessary.

Common questions

Is teduglutide FDA-approved?

Yes. It is approved as Gattex for short bowel syndrome in people who depend on IV nutrition, and the label covers ages 1 and up 2.

What happened to the Gattex REMS?

A REMS is an extra FDA safety program. The FDA removed it for Gattex on August 26, 2026, judging it no longer needed 3.

What dose is on the FDA label?

The label lists 0.05 mg per kg of body weight injected once daily, halved to 0.025 mg/kg for moderate to severe kidney impairment 2. These are label figures, not advice.

What are the main risks of teduglutide?

It may speed the growth of existing tumors, including colon polyps, so the label calls for colonoscopy before and during treatment 2. It can also cause bowel blockage, gallbladder or pancreas problems and fluid overload 2.

What side effects were common in trials?

In adult studies, abdominal pain affected 30% vs 22% on placebo and abdominal swelling 20% vs 2% 2.

Is teduglutide banned in sport?

It is not named on WADA's 2026 Prohibited List 4.

Related compounds

Metabolic & weightFDA-approvedFlashcard

Glucagon

Glucagon Emergency Kit · GlucaGen

Glucagon is a pancreatic hormone that does the opposite of insulin: it tells the liver to release stored sugar.

GastrointestinalFDA-approvedFlashcard

Linaclotide

Linzess · Constella

Linaclotide is a small peptide pill that works inside the gut to treat chronic constipation and constipation-type irritable bowel syndrome.

Sources

  1. GATTEX prescribing information (2021, sequence and mechanism) FDA label
  2. FDA supplement approval letter NDA 203441/S-028: REMS elimination (Aug 2026) Regulatory
  3. WADA 2026 Prohibited List Regulatory

Last reviewed 2026-10-25 · How we research · Found an error? See our corrections policy.